Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Influenza Virus Vaccine USP Quadrivalent, 2012 2013 Formulation · 1 trial · 1 indication
Antibodies against the influenza vaccine virus antigens were measured using a Hemagglutination-inhibition (HAI) assay.
Antibodies against the influenza vaccine virus antigens were measured using a Hemagglutination-inhibition (HAI) assay. Seroconversion was defined as titer\< 10 (1/dil) on Day 0 and post injection titer ≥ 40 (1/dil) on Day 28, or titer ≥10 (1/dil) on Day 0 and a ≥4 fold increase in titer (1/dil) on Day 28).
| Arm | Type | Description |
|---|---|---|
| QIV ID Vaccine Group | EXPERIMENTAL | Participants will receive the intradermal quadrivalent influenza vaccine |
| TIV ID1 Vaccine Group | ACTIVE_COMPARATOR | Participants will receive the trivalent influenza vaccine containing the B strain from the primary (Yamagata) lineage |
| TIV ID2 Group | ACTIVE_COMPARATOR | Participants will receive the intradermal trivalent influenza vaccine containing B strain from the alternate (Victoria) lineage |
| Name | Type | Description |
|---|---|---|
| Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 Formulation | BIOLOGICAL | 0.1mL, Intradermal |
| Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® Intradermal | BIOLOGICAL | 0.1mL, Intradermal |
| Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone Intradermal | BIOLOGICAL | 0.1mL, Intradermal |
Inclusion Criteria: * Aged 18 through 64 years on the day of inclusion * Informed consent form (ICF) has been signed and dated * Able to attend all scheduled visits and to comply with all trial procedures. Exclusion Criteria: * Subject is pregnant, or lactating, or of childbearing potential (to be ...
Top 6 of 9 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sinovac Biotech Ltd. | SVA | 1 | PHASE3 | Quadrivalent influenza vaccine (split virion), inactivated |
| Moderna, Inc. | MRNA | 1 | PHASE3 | mRNA-1018-H5 |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | CDTX | 1 | PHASE3 | CD388 |
| Traws Pharma, Inc. | TRAW | 2 | PHASE2 | TRX-100 |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD4117, AZD5315 |
| GSK plc Sponsored ADR | GSK | 1 | PHASE1 | Flu/COVID-19 mRNA combination vaccine |
Influenza Virus Vaccine USP Quadrivalent, 2012 2013 Formulation is an investigational quadrivalent influenza vaccine developed by Sanofi. It is designed to protect against influenza and was studied in a Phase 3 clinical trial in adults aged 18 through 64 years. It is a vaccine modality given to healthy volunteers.
Influenza Virus Vaccine USP Quadrivalent, 2012 2013 Formulation is used for the prevention of influenza. Its clinical development focused on immunization of adults aged 18 through 64 years against influenza. The Phase 3 study enrolled healthy volunteers in the United States.
Sanofi develops Influenza Virus Vaccine USP Quadrivalent, 2012 2013 Formulation. Sanofi trades under the ticker SNY. The company sponsored the Phase 3 clinical trial of this quadrivalent influenza vaccine candidate.
Influenza Virus Vaccine USP Quadrivalent, 2012 2013 Formulation is in Phase 3 development. The single Phase 3 trial, NCT01712984, has been completed. The vaccine is investigational and is not described as approved.
Influenza Virus Vaccine USP Quadrivalent, 2012 2013 Formulation was studied in one Phase 3 trial, NCT01712984, titled Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years. The trial was completed, enrolled 3,360 participants, and was randomized, double blind, and active controlled.